Reuters logo
Tetraphase's antibiotic succeeds in late-stage trial
December 17, 2014 / 9:22 PM / in 3 years

Tetraphase's antibiotic succeeds in late-stage trial

Dec 17 (Reuters) - Tetraphase Pharmaceuticals Inc said its antibiotic drug to treat complicated intra-abdominal infections was as effective as Merck & co Inc’s ertapenem in a late-stage study.

The drug, eravacycline, treats infections caused by gram-negative bacteria, a type of antibiotic-resistant pathogens, often called superbugs.

Tetraphase shares were up 14.5 percent at $38 in after-hours trading. They closed up 10.6 percent in regular trade on Wednesday, after touching a record high of $33.22 earlier in the session. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Savio D‘Souza)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below